Hochschulschrift
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Hannover, Medizinische Hochschule Hannover, Dissertation, 2017
- Keyword
-
Krebs
Onkologie
- Event
-
Veröffentlichung
- (where)
-
Hannover
- (who)
-
Bibliothek der Medizinischen Hochschule Hannover
- (when)
-
2017
- Creator
- Contributor
- URN
-
urn:nbn:de:gbv:354-20170616193
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Wang, Shuo
- Hillemanns, Peter
- Klinik für Frauenheilkunde und Geburtshilfe
- Bibliothek der Medizinischen Hochschule Hannover
Time of origin
- 2017
Other Objects (12)
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV